AllSci News
Immedica's lurbinectedin-atezolizumab combination gets CHMP nod for ES-SCLC maintenance
Lurbinectedin (Zepzelca) combined with atezolizumab has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products...
Johns Hopkins receives USD 2.86m NIH award for DROIDp brain organoid platform
Johns Hopkins University has received a UM1 cooperative agreement award of USD 2,856,513 from the National Center for Advancing Translational Sciences for...
University of Colorado Anschutz Gates Institute's CD64 CAR T-cell therapy gets IND for AML
The University of Colorado Anschutz Gates Institute announced FDA clearance of an Investigational New Drug application for a CD64-directed CAR T-cell...
FDA approves Regeneron’s Eylea HD for extended five-month dosing interval
The US FDA approved an extended dosing interval for Eylea HD (aflibercept), allowing Regeneron Pharmaceuticals to label the 8 mg intravitreal injection…
UPenn picks up USD 1.1m NHLBI grant for CRISPR base-editing CVD program
The University of Pennsylvania's Kiran Musunuru has received an R35 award from the National Heart, Lung, and Blood Institute totaling USD 1,137,435 in...
Stanford University receives USD 3.09m NCATS award for AI-driven cardiac organoid platform development
Stanford University has received a USD 3.09 million UM1 award from the National Center for Advancing Translational Sciences to develop COIN, a...
Revolution Medicines kickstarts Phase III daraxonrasib trial targeting first-line RAS-driven pancreatic cancer
Revolution Medicines has begun enrolling patients in RASolute 303 (NCT07491445), a Phase 3 trial testing daraxonrasib (RMC-6236) as a first-line treatment...
Adagene and Incyte partner on bispecific immunotherapy combo for MSS CRC
Adagene Inc., (Nasdaq: ADAG), a clinical-stage biotech operating out of Suzhou, China, and San Diego, and Incyte (Nasdaq: INCY), a Delaware-based biopharma,…
AstraZeneca's durvalumab, tremelimumab combo hits PFS goals in liver cancer
AstraZeneca (LSE/STO/NYSE: AZN) reported that the combination of durvalumab (Imfinzi), tremelimumab (Imjudo), lenvatinib, and transarterial...
Cogent files KIT-targeted bezuclastinib plus sunitinib for approval in imatinib-pretreated GIST
Cogent Biosciences has submitted a New Drug Application to the US FDA for bezuclastinib, a selective KIT tyrosine kinase inhibitor, seeking approval for use...
Soligenix’s HyBryte shows improved response and tolerability vs Valchlor in small CTCL study
Soligenix (Nasdaq: SNGX) reported that a small comparative study of synthetic hypericin (HyBryte) versus mechlorethamine (Valchlor) in cutaneous T-cell...
Inovio raises USD 17.5m in underwritten public offering
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) announced a USD 17.5 million underwritten public offering on April 2, 2026, seeking to extend its cash runway as...
Oric's PRC2 inhibitor rinzimetostat combo regimen advances to Phase III trial in mCRPC
ORIC Pharmaceuticals (Nasdaq: ORIC) reported Phase Ib dose optimization data for rinzimetostat in combination with darolutamide in post-abiraterone...
Novo Nordisk follows Lilly's oral GLP-1 approval with data showing Wegovy's weight loss advantage
Novo Nordisk (NVO) reported that oral semaglutide 25 mg (Wegovy) produced approximately 3 percentage points more weight loss than orforglipron in a...
Fore Bio’s plixorafenib receives FDA Breakthrough Therapy status for BRAF-mutated glioma
Fore Biotherapeutics, a registration-stage oncology company headquartered in Philadelphia, Pennsylvania, announced that the FDA has granted Breakthrough Therapy Designation (BTD) to plixorafenib…
The AllSci Brief
Systematic R&D and deal news. Daily.